New mechanisms of action of nsaids: focus on cardiovascular safety
- 作者: Shostak N.A1, Klimenko A.A1, Anichkov D.A1, Kondrashov A.A1
-
隶属关系:
- FSBEI HE RNSMU n.a. N.I. Pirogov of RMH
- 期: 编号 19 (2016)
- 页面: 62-68
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289522
- ID: 289522
如何引用文章
详细
全文:
作者简介
N. Shostak
FSBEI HE RNSMU n.a. N.I. Pirogov of RMH
Email: Shostakkaf@yandex.ru
MD, Prof., Honoured Doctor of the Russian Federation, Head of the Department of Faculty Therapy n.a. Acad. A.I. Nesterov
A. Klimenko
FSBEI HE RNSMU n.a. N.I. Pirogov of RMHDepartment of Faculty Therapy n.a. Acad. A.I. Nesterov
D. Anichkov
FSBEI HE RNSMU n.a. N.I. Pirogov of RMHDepartment of Faculty Therapy n.a. Acad. A.I. Nesterov
A. Kondrashov
FSBEI HE RNSMU n.a. N.I. Pirogov of RMHDepartment of Faculty Therapy n.a. Acad. A.I. Nesterov
参考
- Farkouh M.E. Non-steroidal anti-inflammatory drugs and cardiovascular risk: At crossroads. Trends Cardiovasc Med. 2015;25(8):736-37.
- Ruoff G. Hot Topics in Primary Care: Nonsteroidal Anti- inflammatory Drugs and Cardiovascular Risk: Where Are We Today? J Fam Pract. 2015;64(12 Suppl):S67-70.
- Chuang S.Y., Yu Y., Sheu W.H., Tsai Y.T., Liu X., Hsiung C.A., Tsai H.J. Association of short-term use of nonsteroidal anti-inflammatory drugs with stroke in patients with hypertension. Stroke. 2015;46(4):996-1003.
- Ungprasert P., Srivali N., Thongprayoon C. Nonsteroidal Anti-inflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational Studies. Clin. Cardiol. 2016;39(2):111-18.
- Ungprasert P., Srivali N., Kittanamongkolchai W. Non-steroidal anti-inflammatory drugs and risk of heart failure exacerbation: A systematic review and meta-analysis. Eur J. Intern. Med. 2015;26(9):685-90.
- Agca R., Heslinga S.C., Rollefstad S., et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann. Rheum. Dis. 2016. doi: 10.1136/annrheumdis-2016-209775.
- Roubille C., Richer V., Starnino T., McCourt C., McFarlane A., Fleming P., Siu S., Kraft J., Lynde C., Pope J., Gulliver W., Keeling S., Dutz J., Bessette L., Bissonnette R., Haraoui B. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann. Rheum. Dis. 2015;74:480-89.
- Lindhardsen J., Gislason G.H., Jacobsen S., et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann. Rheum. Dis. 2013; Published Online First 8 June
- Pope J.E., Anderson J.J., Felson D. A metaanalysis of the effects of nonsteroidal antiinflammatory drugs on blood pressure. Arch. Intern. Med. 1993;153:477-84.
- Johnson A., Nguyen T., Day R. Do nonsteroidal anti-inflammatory drugs affect blood pressure? Ann. Intern. Med. 1994;121:289-300.
- Conlin P.R., Moore T.J., Swartz S.L., Barr E., Gazdick L., Fletcher C., DeLucca P., Demopoulos L. Effect of indomethacin on blood pressurelowering by captopril and losartan in hypertensive patients. Hypertension. 2000;36:461-65.
- Morgan T.O., Anderson A., Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am. J. Hypertens. 2000;13:1161-67.
- Morrison A., Ramey D.R., van Adelsberg J., Watson D.J. Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension. Curr. Med. Res. Opin. 2007;23(10):2395-404.
- Sowers J.R., White W.B., Pitt B., Whelton A., Simon L.S., Winer N., Kivitz A., van Ingen H., Brabant T., Fort J.G.; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch. Intern. Med. 2005;165(2):161-68.
- Schwartz J.I., Thach C., Lasseter K.C., Miller J., Hreniuk D., Hilliard D.A., Snyder K.M., Gertz B.J., Gottesdiener K.M. Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet. J. Clin. Pharmacol. 2007;47(12):1521-31.
- Аничков Д.А., Шостак Н.А. Суточный профиль артериального давления у больных метаболическим синдромом и остеоартрозом на фоне терапии нестероидными противовоспалительными препаратами. Клин. мед. 2004;82(12):27-30.
- Reitblat T., Zamir D., Estis L., Priluk R., Drogenikov T., Viskoper J.R. The different patterns of blood pressure elevation by rofecoxib and nabumetone. J. Hum. Hypertens. 2002;16:431-34.
- MacDonald T.M., Reginster J.Y., Littlejohn T.W., Richard D., Lheritier K., Krammer G., Rebuli R. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. J. Hypertens. 2008;26(8):1695-702.
- White W.B., Kent J., Taylor A., Verburg K.M., Lefkowith J.B., Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension. 2002;39(4):929-34.
- Samuelsson B., Morgenstern R., Jakobsson P.J. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol. Rev. 2007;59:207-24.
- Xu S., Rouzer C.A., Marnett L.J. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond. IUBMB Life. 2014;66(12):803-11.
- Asghar W., Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015;23(1):1-16.
- Ungprasert P., Matteson E.L., Thongprayoon C. Nonaspirin nonsteroidal anti-inflammatory drugs and risk of hemorrhagic stroke: a systematic review and meta-analysis of observational studies. Stroke. 2016; 47:356-64.
- Moodley I. Review of the cardiovascular safety of COXIBs compared to NSAIDS. Cardiovasc. J. Afr. 2008;19(2):102-7.
- Garcia Rodriguez L.A., Hernandez-Diaz S. Nonsteroidal anti-inflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003;14(2):240-46.
- Varas-Lorenzo C., Riera-Guardia N., Calingaert B., Castellsague J., Salvo F., Nicotra F., Sturkenboom M., Perez-Gutthann S. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013;22(6):559-70.
- Gislason G.H., Jacobsen S., Rasmussen J.N., Rasmussen S., Buch P., Friberg J., Schramm T.K., Abildstrom S.Z., Kober L., Madsen M., Torp-Pedersen C. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906-13.